Literature DB >> 10736070

Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system.

M Loda1, X Xu, A Pession, A Vortmeyer, F Giangaspero.   

Abstract

The human erythrocyte GLUT-1 is a transmembrane protein which facilitates transport of glucose in the cell in an energy-independent fashion. Neuroectodermal stem cells show strong membrane immunoreactivitry with this marker at early developmental stages in rodents. Membranous expression by undifferentiated neuroectodermal cells gradually decreases while GLUT-1 becomes confined to the endothelial cells, when these acquire blood-brain barrier function. We thus sought to determine whether GLUT-1 expression was limited to embryonal neoplasms of the central nervous system (CNS) which are presumably derived from developmentally arrested neuroectodermal stem cells. Archival material of 40 primary CNS neoplasms were examined for immunoreactivity with anti-GLUT-1. This included both non-embryonal neoplasms (18 astrocytic tumours, one ependymoma and three oligodendroglioma) and embryonal neoplasms (12 cerebellar medulloblastomas, four supratentorial PNETs and two atypical teratoid/rhabdoid tumours (AT/RhT)). In addition, cell lines and nude mice xenografts derived from both undifferentiated and differentiated tumours were assessed for GLUT-1 immunoreactivity by both immunohistochemistry and Western blotting. All embryonal tumours, MBs and PNET xenografts consistently showed GLUT-1 membrane staining. Non-embryonal neoplasms were negative except for vascular staining. Membrane protein fraction of embryonal tumours cell lines immunoreacted by immunoblot with GLUT-1, whereas the glioblastoma cell line was negative. Expression of GLUT-1 supports the stem cell nature of the cells of origin of MBs, supratentorial PNET and AT/RhTs. As a result, GLUT-1 is a useful marker to define the embryonal nature of CNS neoplasms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736070     DOI: 10.1046/j.1365-2990.2000.00225.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  6 in total

1.  Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.

Authors:  Melissa E Smith; Velasco Cimica; Srinivasa Chinni; Suman Jana; Wade Koba; Zhixia Yang; Eugene Fine; David Zagzag; Cristina Montagna; Ganjam V Kalpana
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 2.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 3.  Cytogenetic findings in pediatric radiation-induced atypical meningioma after treatment of medulloblastoma: case report and review of the literature.

Authors:  María Sol Brassesco; Elvis Terci Valera; Luciano Neder; Julia Alejandra Pezuk; Ricardo Santos Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Neurooncol       Date:  2012-10-18       Impact factor: 4.130

4.  A novel, integrated PET-guided MRS technique resulting in more accurate initial diagnosis of high-grade glioma.

Authors:  Ellen S Kim; Martin Satter; Marilyn Reed; Ronald Fadell; Arash Kardan
Journal:  Neuroradiol J       Date:  2016-04-27

5.  Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II.

Authors:  Florian Stockhammer; Andreas von Deimling; Michael Synowitz; Cristiane Blechschmidt; Frank K H van Landeghem
Journal:  J Mol Histol       Date:  2008-08-26       Impact factor: 2.611

6.  The protective effects of insulin and natural honey against hippocampal cell death in streptozotocin-induced diabetic rats.

Authors:  Iraj Jafari Anarkooli; Hossein Barzegar Ganji; Maryam Pourheidar
Journal:  J Diabetes Res       Date:  2014-03-13       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.